American Thoracic Society - Sanofi Investor Call

sanofi Lead with Dupixent® in Type 2 Positive pivotal data across 12 indications in Dermatology, Respiratory, and Gastroenterology EN 57 AD 18y+ PN 18y+ Asthma EoE 12+ 12y+ AD CSU 12-18y 12y+ Asthma 6-11y EoE 1-11y CRSWNP 18+ COPD 18y+ AD 6-11y AD 6m - 5y Studies in 7 additional indications ongoing: BP, CPUO, UC, EG, Peds (Asthma, PN, CSU) Dupixent® is under investigation and not yet approved by any regulatory agency to treat these indications First-in-Class biologics Efficacy & safety data across multiple Type 2 indications 60+ clinical trials with 10,000+ patients Safety data up to 5 years 1st FDA approval March 2017 > Approved in children as young as 6 months > More than 600,000 patients on therapy globally 11 ATS Investor Call

View entire presentation